Literature DB >> 14600603

Metastatic breast cancer: overview of treatment.

S M Ali1, H A Harvey, Allan Lipton.   

Abstract

Patients with metastatic breast cancer have a median survival of 2 to 3 years. Twenty percent of the patients who present with bone-only metastasis will be alive at 5 years from diagnosis. Current therapies are aimed at improving the quality of life, symptom control, and prolongation of survival. Newer endocrine and chemotherapeutic drugs are available to the medical oncologist for care of patients with metastatic breast cancer. We will briefly review the new advances in the treatment of metastatic breast cancer.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14600603     DOI： 10.1097/01.blo.0000092981.12414.7b

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.176


  21 in total

1.  A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Authors:  Monica M Reinholz; Shawn P Zinnen; Amylou C Dueck; David Dingli; Gregory G Reinholz; Leslie A Jonart; Kathleen A Kitzmann; Amy K Bruzek; Vivian Negron; Abdalla K Abdalla; Bonnie K Arendt; Anthony J Croatt; Luis Sanchez-Perez; David P Sebesta; Harri Lönnberg; Toshiyuki Yoneda; Karl A Nath; Diane F Jelinek; Stephen J Russell; James N Ingle; Thomas C Spelsberg; Henry B F Hal Dixon; Alexander Karpeisky; Wilma L Lingle
Journal:  Bone       Date:  2010-03-15       Impact factor: 4.398

2.  In vitro and in vivo antitumorigenic activity of a mixture of lysine, proline, ascorbic acid, and green tea extract on human breast cancer lines MDA-MB-231 and MCF-7.

Authors:  M Waheed Roomi; Vadim Ivanov; Tatiana Kalinovsky; Aleksandra Niedzwiecki; Matthias Rath
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.

Authors:  R Kreienberg; U-S Albert; M Follmann; I B Kopp; T Kühn; A Wöckel
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-06       Impact factor: 2.915

Review 4.  EGFR signaling in breast cancer: bad to the bone.

Authors:  John Foley; Nicole K Nickerson; Seungyoon Nam; Kah Tan Allen; Jennifer L Gilmore; Kenneth P Nephew; David J Riese
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

5.  Overexpression of ILK1 in breast cancer associates with poor prognosis.

Authors:  Hong-Jian Yang; Ya-Bing Zheng; Ting Ji; Xian-Feng Ding; Cong Zhu; Xing-Fei Yu; Zhi-Qiang Ling
Journal:  Tumour Biol       Date:  2013-07-07

6.  Mechanoresponsive stem cells to target cancer metastases through biophysical cues.

Authors:  Linan Liu; Shirley X Zhang; Wenbin Liao; Henry P Farhoodi; Chi W Wong; Claire C Chen; Aude I Ségaliny; Jenu V Chacko; Lily P Nguyen; Mengrou Lu; George Polovin; Egest J Pone; Timothy L Downing; Devon A Lawson; Michelle A Digman; Weian Zhao
Journal:  Sci Transl Med       Date:  2017-07-26       Impact factor: 17.956

7.  EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase.

Authors:  Thejass Punathil; Trygve O Tollefsbol; Santosh K Katiyar
Journal:  Biochem Biophys Res Commun       Date:  2008-08-08       Impact factor: 3.575

Review 8.  MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells.

Authors:  Amir Sadra Zangouei; Maliheh Alimardani; Meysam Moghbeli
Journal:  Cancer Cell Int       Date:  2021-04-15       Impact factor: 5.722

9.  Gallotannin-rich Caesalpinia spinosa fraction decreases the primary tumor and factors associated with poor prognosis in a murine breast cancer model.

Authors:  Claudia Urueña; Juan Mancipe; John Hernandez; Diana Castañeda; Luis Pombo; Alejandra Gomez; Alexzander Asea; Susana Fiorentino
Journal:  BMC Complement Altern Med       Date:  2013-04-03       Impact factor: 3.659

10.  Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C-deficient mice.

Authors:  John Cha; M Waheed Roomi; Vadim Ivanov; Tatiana Kalinovsky; Aleksandra Niedzwiecki; Matthias Rath
Journal:  Int J Oncol       Date:  2012-11-21       Impact factor: 5.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.